1411 ET - Elevance Health cut its guidance by slightly more than expected, but still within the realm of possibilities investors anticipated, Guggenheim analysts say in a note. Shares could be volatile given the updated outlook, but in the longer term, the new $30 2025 adjusted EPS baseline should give the stock a more attractive jump-off for next year, given the importance of health insurance exchange repricing and normalizing Medicaid costs for the company's long-term earnings growth target, the analysts say. Elevance slides 11%. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
July 17, 2025 14:11 ET (18:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。